Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303017 · ClinicalTrials.gov registry record · NA
Safety, Efficacy and Acceptability of Flavocoxid (Limbrel)A Pilot Study
A NA study, sponsored by Primus Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT00303017 is a NA study that has completed, run by Primus Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT00303017, a NA study, has completed, sponsored by Primus Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
safety, efficacy and acceptability of Flavocoxid
Interventions
- DRUG Naproxen
- DIETARY_SUPPLEMENT flavocoxid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2006-03 |
| Est. Completion | 2006-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00303017
The ClinicalTrials.gov registry entry for NCT00303017 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Primus Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Naproxen is the first listed.
NCT00303017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00303017 about?
NCT00303017 is a clinical study titled "Safety, Efficacy and Acceptability of Flavocoxid (Limbrel)A Pilot Study". safety, efficacy and acceptability of Flavocoxid
What is the current status of trial NCT00303017?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2006-03. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00303017?
The interventions under investigation include: Naproxen (DRUG), flavocoxid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00303017?
This trial is sponsored by Primus Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.